EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial

Jannik Rousel iD, Mahdi Saghari iD, Lisa Pagan iD, Andreea Nădăban iD, Tom Gambrah, Bart Theelen iD, Marieke L de Kam, Jorine Haakman iD, Hein E C van der Wall iD, Gary L Feiss, Tessa Niemeyer-van der Kolk, Jacobus Burggraaf iD und 3 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241814315 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jannik Rousel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Human Drug Research, 2333 CL Leiden, The Netherlands. Hauptthemen laut MEDLINE: Dermatitis, Seborrheic, Malassezia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cutanea Life Sciences, Wayne, Pennsylvania, USA, Maruho Co. Ltd., Kyoto, Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Facial seborrheic dermatitis (SD) is an inflammatory skin disease characterized by erythematous and scaly lesions on the skin with high sebaceous gland activity. The yeast Malassezia is regarded as a key pathogenic driver in this disease, but increased Staphylococcus abundances and barrier dysfunction are implicated as well. Here, we evaluated the antimicrobial peptide omiganan as a treatment for SD since it has shown both antifungal and antibacterial activity. A randomized, patient- and evaluator-blinded trial was performed comparing the four-week, twice daily topical administration of omiganan 1.75%, the comparator ketoconazole 2.00%, and placebo in patients with mild-to-moderate facial SD. Safety was monitored, and efficacy was determined by clinical scoring complemented with imaging. Microbial profiling was performed, and barrier integrity was assessed by trans-epidermal water loss and ceramide lipidomics. Omiganan was safe and well tolerated but did not result in a significant clinical improvement of SD, nor did it affect other biomarkers, compared to the placebo. Ketoconazole significantly reduced the disease severity compared to the placebo, with reduced Malassezia abundances, increased microbial diversity, restored skin barrier function, and decreased short-chain ceramide Cer[NSc34]. No significant decreases in Staphylococcus abundances were observed compared to the placebo. Omiganan is well tolerated but not efficacious in the treatment of facial SD. Previously established antimicrobial and antifungal properties of omiganan could not be demonstrated. Our multimodal characterization of the response to ketoconazole has reaffirmed previous insights into its mechanism of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, SeborrheicMalasseziaHumansKetoconazoleAntifungal AgentsAntimicrobial PeptidesTreatment OutcomeAntimicrobial Cationic Peptides

Stichwörter der Autor:innen

MalasseziaStaphylococcusketoconazolemultimodalomigananseborrheic dermatitisskin barrier

Substanzen

KetoconazoleAntifungal AgentsAntimicrobial PeptidesOmigananAntimicrobial Cationic Peptides

Autor:innen und Institutionen

  • Centre for Human Drug Research, 2333 CL Leiden, The Netherlands.
  • Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
  • Leiden University Medical Center, Leiden University, 2333 ZA Leiden, The Netherlands.
  • Westerdijk Fungal Biodiversity Institute, 3508 AD Utrecht, The Netherlands.
  • Cutanea Life Sciences, Wayne, PA 19087, USA.
  • Department of Dermatology, Erasmus Medical Centre, 3015 GD Rotterdam, The Netherlands.

ORCID-Profile: Jannik Rousel, Mahdi Saghari, Lisa Pagan, Andreea Nădăban, Bart Theelen, Jorine Haakman, Hein E C van der Wall, Jacobus Burggraaf

Förderung

  • Cutanea Life Sciences, Wayne, Pennsylvania, USA
  • Maruho Co. Ltd., Kyoto, Japan

Zitieren

APA

Rousel, J., Saghari, M., Pagan, L., Nădăban, A., Gambrah, T., Theelen, B., de Kam, M. L., Haakman, J., van der Wall, H. E. C., Feiss, G. L., Niemeyer-van der Kolk, T., Burggraaf, J., Bouwstra, J. A., Rissmann, R., & van Doorn, M. B. A. (2023). Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241814315

Vancouver

Rousel J, Saghari M, Pagan L, Nădăban A, Gambrah T, Theelen B, et al. Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241814315

BibTeX
@article{Rousel2023,
  author = {Rousel, Jannik and Saghari, Mahdi and Pagan, Lisa and Nădăban, Andreea and Gambrah, Tom and Theelen, Bart and de Kam, Marieke L and Haakman, Jorine and van der Wall, Hein E C and Feiss, Gary L and Niemeyer-van der Kolk, Tessa and Burggraaf, Jacobus and Bouwstra, Joke A and Rissmann, Robert and van Doorn, Martijn B A},
  title = {Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241814315}
}
Kostenlos starten →